Evidence map›Paper›PMID 35646496›Full record

ArticlePlastic and reconstructive surgery. Global open2022

Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials.

Lawrence S Bass, Joely Kaufman-Janette, John H Joseph, Michael S Kaminer, James Clark, Sabrina G Fabi, Michael H Gold, Bruce E Katz, Kappa Peddy, Joel Schlessinger and 7 more

Open access · goldAbstract read
In one paragraph

Article in Plastic and reconstructive surgery. Global open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Cellulite: Current Understanding and Treatment.Aesthetic surgery journal. Open forum · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Lawrence S BassBass Plastic Surgery PLLC, New York, N.Y.
Joely Kaufman-JanetteSkin Associates of South Florida, Coral Gables, Fla.
John H JosephJohn H. Joseph Facial Plastic and Reconstructive Surgery, Encino, Calif.
Michael S KaminerSkinCare Physicians, Chestnut Hill, Mass.
James ClarkCharlottesville Medical Research, Charlottesville, Va.
Sabrina G FabiCosmetic Laser Dermatology, A West Dermatology Company, San Diego, Calif.
Michael H GoldTennessee Clinical Research Center, Nashville, Tenn.
Bruce E KatzJuva Skin & Laser Center, New York, N.Y.
Kappa PeddyThe Education & Research Foundation, Lynchburg, Va.
Joel SchlessingerSkin Specialists, P.C., Omaha, Neb.
V Leroy YoungMercy Health Research, Washington, Mo.
David HurleyEndo Pharmaceuticals, Inc., Malvern, Pa.
Michael P McLaneEndo Pharmaceuticals, Inc., Malvern, Pa.
Saji VijayanEndo Pharmaceuticals, Inc., Malvern, Pa.
Genzhou LiuEndo Pharmaceuticals, Inc., Malvern, Pa.
Matthew W DavisEndo Pharmaceuticals, Inc., Malvern, Pa.
Mitchel P GoldmanCosmetic Laser Dermatology, A West Dermatology Company, San Diego, Calif.
Chestnut Hill College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Collagen-rich fibrous septae and subcutaneous adipose protrusions play a role in cellulite pathophysiology. Collagenase clostridium histolyticum-aaes (CCH-aaes) injection causes enzymatic release of septae to resolve cellulite depressions and create a skin smoothing effect. This analysis pooled data from two identically designed, phase-3, randomized, double-blind, placebo-controlled studies to examine the efficacy and safety of CCH-aaes. Methods: Adult women with moderate/severe cellulite (3-4 on Clinician Reported Photonumeric Cellulite Severity Scale and Patient Reported Photonumeric Cellulite Severity Scale) on the buttocks received up to three treatment sessions (Days 1, 22, and 43) of subcutaneous CCH-aaes 0.84 mg or placebo per treatment area. Composite and individual component response (≥2-level or ≥1-level improvement from baseline in Patient Reported Photonumeric Cellulite Severity Scale and/or Clinician Reported Photonumeric Cellulite Severity Scale) and additional patient-reported outcomes were determined at Day 71. Results: Analysis included 424 CCH-aaes-treated and 419 placebo-treated women. CCH-aaes-treated women were 5.9 times more likely than placebo-treated women to be ≥2-level composite responders at Day 71 (odds ratio [95% confidence interval], 5.9 [2.2-15.4]; Conclusion: CCH-aaes treatment significantly improved moderate-to-severe buttock cellulite appearance and was generally well tolerated.

Identifiers

PMID35646496
PMCPMC9132528
OpenAlexW4281493643

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.